The purpose of this study was to develop a @entity2101 ( @entity2101 ) matrix implant as a sustained antimicrobial delivery system for local prevention and/or treatment of @entity4034 . Implants (200 mg) of @entity2101 containing 2.5% (5 mg), 7.5% (15 mg), 15.0% (30 mg) and 20.0% (40 mg) of @entity2177 ( @entity5443 ), were prepared by direct compression of dry blends. @entity95 were administered six 2.5, two 7.5, one 15.0 or one 20.0%- @entity5443 implants along the femur between the quadriceps and biceps femoris muscles to determine systemic (serum) versus local (muscle and bone) @entity5443 concentrations over 1 month. Blood samples were taken throughout the study for @entity5443 assay. Muscle and femur were collected at 3, 7, 14, 21 and 28 days after implantation for host response evaluation and @entity5443 assay. Residual polymer was explanted to determine the remaining dose of @entity5443 . All animals remained healthy during the study. Local tissue reaction was mild and limited to the implantation site. Serum @entity5443 concentrations remained low regardless of implant loading. Increased drug loading resulted in a higher and longer release of @entity5443 in muscle and in bone. Local @entity5443 concentrations were detected largely in excess of the MIC over 28 days with 20.0%- @entity5443 implants. More residual @entity5443 in polymer was detected over a longer period of time at high loading. These results strongly support the development of @entity2101 implants for local antibacterial therapy.

Characterization of @entity2101 matrix implants. 2. In vivo release of XXXX .

@entity5443 :: ('CHEBI:209807', 'Chemical') :: ['CFX'] @entity4034 :: ('MESH:D010019', 'Disease') :: ['osteomyelitis'] @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin'] @entity95 :: ('9986', 'Species') :: ['Rabbits'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['crosslinked high amylose starch', 'CLHAS']
@entity2177 :: (MESH:D002939,Chemical) :: ['ciprofloxacin']
